Author/Creator: Wu, Shenhong - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Wu, Shenhong

1. Alopecia With Endocrine Therapies in Patients With Cancer. (13th September 2013)

Authors:: Saggar, Vishal; Wu, Shenhong; Dickler, Maura N.; Lacouture, Mario E.
Journal:: Oncologist
Issue:: Volume 18:Number 10(2013)
Page Start:: 1126
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma. (3rd June 2018)

Authors:: Zarrabi, Kevin; Wu, Shenhong
Journal:: Expert opinion on biological therapy
Issue:: Volume 18:Number 6(2018)
Page Start:: 695
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer. (25th November 2016)

Authors:: Garcia, Christine A.; Wu, Shenhong
Journal:: Cancer investigation
Issue:: Volume 34:Number 10(2016)
Page Start:: 521
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis. (14th September 2017)

Authors:: Rogers, Sherise C.; Garcia, Christine A.; Wu, Shenhong
Journal:: Cancer investigation
Issue:: Volume 35:Number 8(2017)
Page Start:: 552
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis. (7th February 2020)

Authors:: Sher, Amna F.; Golshani, Gol M.; Wu, Shenhong
Journal:: Cancer investigation
Issue:: Volume 38:Number 2(2020)
Page Start:: 130
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis. (June 2022)

Authors:: Nocco, Sarah; Andriano, Tyler M.; Bose, Arpita; Chilov, Marina; Godwin, Kendra; Dranitsaris, George; Wu, Shenhong; Lacouture, Mario E.; Roeker, Lindsay E.; Mato, Anthony R.; Markova, Alina
Journal:: Critical reviews in oncology/hematology
Issue:: Volume 174(2022)
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

7. Incidence and Risk of High-grade Stomatitis with mTOR Inhibitors in Cancer Patients. (16th March 2015)

Authors:: Shameem, Raji; Lacouture, Mario; Wu, Shenhong
Journal:: Cancer investigation
Issue:: Volume 33:Number 3(2015)
Page Start:: 70
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

8. Incidence and risk of rash to mTOR inhibitors in cancer patients – a meta-analysis of randomized controlled trials. (January 2015)

Authors:: Shameem, Raji; Lacouture, Mario; Wu, Shenhong
Journal:: Acta oncologica
Issue:: Volume 54:Number 1(2015)
Page Start:: 124
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

9. Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis. (21st October 2019)

Authors:: Zhu, Xiaolei; Wu, Shenhong
Journal:: Cancer investigation
Issue:: Volume 37:Number 9(2019)
Page Start:: 478
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

10. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. Issue 1 (December 2017)

Authors:: Zarrabi, Kevin; Fang, Chunhui; Wu, Shenhong
Journal:: Journal of hematology & oncology
Issue:: Volume 10:Issue 1(2017)
Page Start:: 1
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗